Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will compare grade 2 or greater late skin toxicities of concomitant letrozole-radiotherapy and radiotherapy followed by letrozole as adjuvant therapy for postmenopausal women with receptor (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) positive tumors. Each drug will be prescribed for 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

NCT00375752

Breast Neoplasms

TERMINATED PHASE4

Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy

NCT00247650

Breast Cancer

COMPLETED PHASE2

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

NCT00238290

Breast Cancer

COMPLETED PHASE2

Dose Escalated Concomitant Boost Radiotherapy for Early Breast Cancer

NCT07021846

Breast Cancer

RECRUITING NA

Intraoperative Radiotherapy After Local Recurrence in Breast Cancer

NCT02386371

Breast Carcinoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is an open-label randomized multicenter phase II study.

A ratio of 1 to 1 will be used for the randomization process between the two arms:

* Arm A : Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
* Arm B : Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.

All patients will be followed every 3 months for toxicities, disease status and for survival until death.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.

Group Type EXPERIMENTAL

Letrozole - Concomitant

Intervention Type DRUG

B

Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.

Group Type EXPERIMENTAL

Letrozole - Sequential

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Letrozole - Concomitant

Intervention Type DRUG

Letrozole - Sequential

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Compliant postmenopausal women
* Conservative breast cancer surgery
* Extension evaluation of disease will be proven negative
* Patients with tumor negative margins
* Patients will be classified as T1, T2, T3; Sentinel node negative, N0, N1 or N2; M0.
* Receptor positive tumors (ER and/or PgR = 10 fmol/mg cytosol protein; or = 10% of the tumor cells positive by immunocytochemical evaluation).
* Adequate marrow function (polynuclear neutrophils \>= 1200.10\^9/l, platelets \>= 100.10\^9/l, and hemoglobin \>= 10 g/dl).
* Hepatic function (bilirubin \>= 30 µmol/l, ALT (SGPT) or AST (SGOT) \>= 1.5 x upper limit of the institution) and cholesterol level \<2 x upper limit of the institution.
* Must be geographically accessible for follow-up.
* Written and dated informed consent

Exclusion Criteria

* Patients with distant metastases.
* Bilateral breast cancer (concomitant or prior) except in situ lesion, either ductal or lobular, of the contralateral breast.
* Patients staged T4 or N3 or treated by not conservative surgery (radical mastectomy).
* Patients with neoadjuvant chemotherapy or hormonal therapy.
* Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years.
* Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.
* Patients treated with systemic investigational drugs within the past 30 days.
* Breast cancer chemoprevention with anti-estrogens
* Hormone replacement therapy (HRT) not stopped at least 4 weeks before randomization
* Patients known to be HIV positive (no specific tests are required to determine the eligibility).

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No